|
SIGN-UP NOW!
Click to become a The VoiceAmerica Talk Member for Free!
|
|
|
|
|
|
|
|
|
|
|
|
The Ellis Martin Report
Archives Available
May 18th 2020: Zhittya Genesis Medicine: Repairing Lung Damage from Covid-19
|
|
In this episode of The Ellis Martin Report we’ll direct the entire show to discussion of Covid-19 in a way that primarily discusses health and economics. Our first two segments will feature Zhittya Genesis Medicine which is currently researching a repair through an aerosol inhaler designed for the afflicted lungs of Covid patients. Company president Dr. Jack Jacobs will give us a report on his findings. We then have a full ad hoc discussion with Zhittya CEO Dan Montano where he’ll share his thoughts about the economics aspect of the lockdown where he mentions countries such as Sweden rema
|
|
Read more
|
|
|
Tune in
|
|
Archives Available on VoiceAmerica Business Channel
|
|
|
|
|
|
|
|
Dr. Jack Jacobs
|
|
Dr. Jacobs received his Ph.D. in molecular biology from the Washington University School of Medicine, St. Louis, Missouri and his B.S. in chemistry from Davidson College in North Carolina. He was recruited as an Assistant Professor to the University of Texas, San Antonio, where he established his own laboratory and received numerous awards for his research on peptide hormones, including a prestigious Research Career Development Award from the National Institutes of Health. Dr. Jacobs was recruited away from academia to Merck, where he established a Department of Biological Chemistry composed of approximately 30 researchers who focused on the discovery of new agents to inhibit blood clotting.
|
|
Read more
|
|
|
Dan Montano
|
|
Daniel Montano is the CEO of Zhittya Genesis Medicine Inc. For the last 21 years, he has been advancing a group of biological drugs which in USA FDA clinical trials has demonstrated that it triggers the growth of new blood vessels in ischemic tissues, a medical treatment we call "Therapeutic Angiogenesis". He believes their drug treatment (if and when approved by the USA FDA) can treat the cause of death and suffering which affects over 50% of the adults in the world. He has expended over $140 million, so far advancing this medicine through research and clinical trials to seek regulatory approval. Presently we are advancing 19 medical indications.
|
|
Read more
|
|
|
Peter Bahrke
|
|
Aecor Partners is an independent advisory firm focused on providing financial advice on mergers, acquisitions, restructurings, financings and capital advisory to corporations and institutions.
Senior partners represent a mix of extensive experience from international and Nordic investment banks, consulting, restructuring and principal investment with an extensive investor network for capital raisings.
|
|
Read more
|
|
|
|
|
|
Connect with VoiceAmerica
|
|
|
|
|
|
|
|
